Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
Inventors
Given, Bruce • Christianson, Dawn • Hamilton, James C. • Li, Zhen • Zhu, Rui • Wooddell, Christine I. • Pei, Tao
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.
Core Innovation
The disclosed invention concerns methods for treating alpha-1 antitrypsin deficiency in a human subject using an AAT RNAi Drug Substance. The drug substance comprises an annealed, chemically modified sense and antisense RNA duplex that targets AAT mRNA and is linked to a trivalent N-acetyl-galactosamine targeting group for hepatocyte delivery. The drug substance is administered as a pharmaceutical composition under recurring and staged regimens, while specific sequence and regimen details are [procedural detail omitted for safety].
A Phase I study reports that administration of the drug substance substantially reduces serum AAT, with suppression persisting during follow-up while placebo levels remain comparatively stable. The background section is not included, so the problem identified in that section is not explicitly described in the patent. Results vary by dose and regimen, with specific dose amounts and administration timing [procedural detail omitted for safety].
Claims Coverage
The claims include four independent claims directed to treating AATD in a human subject with a pharmaceutical composition containing the specified AAT RNAi Drug Substance, encompassing four inventive features.
Recurring administration regimen
Independent claim 1 covers treatment of AATD using a pharmaceutical composition containing the specified annealed AAT RNAi duplex administered by subcutaneous injection on a recurring schedule, wherein dose and interval comprise [procedural detail omitted for safety].
Alternative recurring administration regimen
Independent claim 2 covers treatment of AATD using the specified annealed AAT RNAi duplex in a pharmaceutical composition administered by subcutaneous injection on an extended recurring schedule distinct from claim 1, wherein dose and interval comprise [procedural detail omitted for safety].
Staged administration regimen
Independent claim 3 covers treatment of AATD using the specified annealed AAT RNAi duplex in a pharmaceutical composition, with an initial administration followed by later administrations, wherein dose and timing comprise [procedural detail omitted for safety].
Specified-dose staged administration regimen
Independent claim 21 covers treatment of AATD using a specified dose amount of the annealed AAT RNAi duplex in a pharmaceutical composition, with an initial administration followed by later administrations, wherein dose amount and timing comprise [procedural detail omitted for safety].
The independent claims cover recurring and staged administration of a pharmaceutical composition containing the specified modified AAT RNA duplex for treatment of AATD, differing in administration schedule and specified dose.
Stated Advantages
The Phase I study reports substantial reduction of serum AAT following administration of the AAT RNAi Drug Substance, with suppression persisting during follow-up.
Documented Applications
Treatment of alpha-1 antitrypsin deficiency in human subjects.
Treatment of AATD-associated liver disease and lung-related conditions.
Interested in licensing this patent?